

Amendments to the Claims:

This claim listing will replace all prior versions and listings of claims in the application:

Claim Listing:

1. (Previously presented) A modified phosphorothioate oligonucleotide for inhibiting specific gene expression with reduced side effects, the modification consisting of a modified CpG dinucleotide, wherein the oligonucleotide is complementary to a portion of a genomic region or gene for which inhibition of expression is desired, or to RNA transcribed from such a gene, and wherein the modified CpG is 2'-O-substituted CpG.
2. (canceled)
3. (Withdrawn) A method for providing a CpG-containing phosphorothioate oligonucleotide with reduced side effects of splenomegaly and depletion of platelets when administered to a mammal, comprising administering to the mammal an oligonucleotide comprising a modified CpG dinucleotide, wherein the oligonucleotide is complementary to a portion of a genomic region or gene for which inhibition of expression is desired, or to RNA transcribed from such a gene, and wherein the modified CpG is selected from the group consisting of alkylphosphonate CpG, phosphotriester CpG, stereospecific phosphorothioate CpG, phosphoramidate CpG, inverted CpG and 2'-5' CpG.
4. (Withdrawn) A method for providing a CpG-containing phosphorothioate oligonucleotide with reduced side effects to an individual with a disease caused by aberrant gene expression, the method comprising administering to an individual having the disease an oligonucleotide comprising a modified CpG dinucleotide, wherein the oligonucleotide is complementary to a portion of a genomic region or gene that is aberrantly expressed, or to RNA transcribed from such a gene, and wherein the modified CpG is selected from the group consisting of alkylphosphonate CpG, phosphotriester CpG, stereospecific phosphorothioate CpG, phosphoramidate CpG, inverted CpG and 2'-5' CpG.

5. (Withdrawn) A method for reducing side effects of a CpG-containing phosphorothioate oligonucleotide administered to a mammal, comprising:
 - (a) providing a CpG-containing phosphorothioate oligonucleotide having a CpG modification selected from the group consisting of alkylphosphonate CpG, inverted CpG, stereospecific phosphorothioate CpG, phosphotriester CpG, phosphoramidate CpG, and 2'-5' CpG; and
 - (b) administering the modified CpG-containing phosphorothioate oligonucleotide to the mammal,wherein administration of the modified CpG-containing phosphorothioate oligonucleotide results in fewer side effects than the administration of an unmodified CpG-containing phosphorothioate oligonucleotide.
6. – 15. (canceled)
16. (Withdrawn) A method for providing a CpG-containing phosphorothioate oligonucleotide with reduced side effects of splenomegaly and depletion of platelets when administered to a mammal, comprising administering to the mammal a modified oligonucleotide wherein the modification consists of a modified CpG dinucleotide, wherein the oligonucleotide is complementary to a portion of a genomic region or gene for which inhibition of expression is desired, or to RNA transcribed from such a gene, and wherein the modified CpG is 2'-O-substituted CpG.
17. (Withdrawn) A method for providing CpG-containing phosphorothioate oligonucleotide with reduced side effects to an individual with a disease caused by aberrant gene expression, the method comprising administering to an individual having the disease a modified oligonucleotide wherein the modification consists of a modified CpG dinucleotide, wherein the oligonucleotide is complementary to a portion of a genomic region or gene that is aberrantly expressed, or to RNA transcribed from such a gene, and wherein the modified CpG is 2'-O-substituted CpG.
18. (Withdrawn) A method for reducing side effects of a CpG-containing phosphorothioate oligonucleotide administered to a mammal, comprising:

- (a) providing a modified CpG-containing phosphorothioate oligonucleotide wherein the modification consists of a 2'-O-substituted CpG modification; and
- (b) administering the modified CpG-containing phosphorothioate oligonucleotide to the mammal,

wherein administration of the modified CpG-containing phosphorothioate oligonucleotide results in fewer side effects than the administration of an unmodified CpG-containing phosphorothioate oligonucleotide.